Neuroprotective agent 16
Neuroprotective agent 16 is a blood-brain barrier-permeable neuroprotective agent. Neuroprotective agent 16 effectively scavenges DPPH and ABTS radicals, with IC50 values of 7.98 μM and 5.50 μM, respectively. Neuroprotective agent 16 exhibits anti-inflammatory, antioxidant, and DNA damage-reducing activities. Neuroprotective agent 16 can be used in research on diseases such as ischemic stroke.
For research use only. We do not sell to patients.
- Formula: C20H24ClN3O3
- Molecular Weight:389.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
IL-17 |
Neuroprotective agent 16 (Compound B16) (0.1-10 μM; 24 h) protects SH-SY5Y cells against damage induced by tBHP and/or OGD/R[1].
Neuroprotective agent 16 (1 μM; 24 h) alleviates tBHP-induced cell cycle arrest and DNA damage in SH-SY5Y cells, scavenges excessive intracellular ROS, and maintains mitochondrial membrane potential[1].
Neuroprotective agent 16 (0.1-10 μM; 24 h) inhibits the secretion of TNF-α and IL-17 in tBHP-treated BV2 microglial cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y cell treated tBHP and/or OGD/R
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:24 h
-
Result:Improved cell morphology and increased cell survival rates.
-
Cell Line:SH-SY5Y cells treated tBHP
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Reversed tBHP-induced G2/M phase arrest: increased S-phase cells from 1.49% to 6.97% and decreased G2/M-phase cells from 28.35% to 18.15%.
Significantly reduced intracellular γ-H2AX expression (a marker of DNA double-strand breaks) induced by tBHP.
-
Cell Line:BV2 microglial cells treated tBHP
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent decrease in TNF-α and IL-17 expression levels in tBHP-stimulated BV2 cells.
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-∞ | MRT0-∞ |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 20.6 h | 0.08 h | 30826.1 ng/mL | 23999.8 ng·h/mL | 34356.5 ng·h/mL | 21.4 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (male, 7 weeks old, 25-35 g, MCAO/R modeling)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced cerebral infarct volume significantly from 43.23% to 3.59% at 5 mg/kg.
Restored cerebral blood flow in the ischemic region, improved body weight recovery, and increased scores from balance beam, pole climbing, and corner tests.
Reduced perivascular white gaps and improved pyramidal cell morphology in hippocampal CA1 region and reduced neuronal edema/necrosis and preserved Nissl bodies. Significantly recovered Occludin and ZO-1 protein expression.
Chemical Information
-
Molecular Weight 389.88
-
Formula C20H24ClN3O3
-
SMILES
O=C(C1=NN(C(O)=C1)C2=C(C=C(C=N2)Cl)C)O[C@H]3C[C@H]4CC[C@@]3(C4(C)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz